Novelties in the treatment of myelofibrosis and polycythemia vera 2021

Professor Srdan Verstovsek speak about the novelties and state of the art treatment presented at ASH 2021.

Risks for Hospitalization and Death Among Patients with Blood Disorders from the ASH RC COVID-19 Registry for Hematology

Patients with blood cancers, particularly those with more advanced disease, are at increased risk for serious COVID-19 outcomes, including an elevated chance of severe illness or death from infection, according to an analysis of more than 1,000 patients in the ASH RC COVID-19 Registry for Hematology.

Novelties in the treatment of multiple myeloma 2021

Professor Andrzej Jakubowiak speak about the novelties and state of the art treatment presented at ASH 2021.

Antibody Response to Vaccination with Myeloid and Lymphoid Neoplasms

Professor Susanne Saussele speaks about antibody response to vaccination with BNT162b2, mRNA-1273, and ChADOx1 in Patients with Myeloid and Lymphoid Neoplasms. In general, patients with hematological diseases are predisposed to develop infections. Severe COVID-19 infection associated with high mortality is more likely in these patient cohorts compared to the general population. Due to immune defects related to the primary disease and/or to immunosuppressive treatment regimes, vaccination efficacy may be reduced in patients with hematological diseases. So far, data on this area are limited.

Novelties on the treatment of non-Hodgkin lymphoma 2021

The main topics that Professor Umberto Vitolo speaks about: CAR T-cell studies, POLARIS study, R-CHOP timing.

Results from the Randomized Phase 3 Transform Study

Professor Manali Kamdar speaks about Lisocabtagene Maraleucel, a CD19-Directed Chimeric Antigen Receptor T Cell Therapy, Versus Standard of Care with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation As Second-Line Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma.

Antithrombin Deficiency Registry, an Update

Professor Zsuzsanna Bereczky introduce the Antithrombin Deficiency Registry that was established in 2020.

Abelacimab for Prevention of Venous Thromboembolism

Prof.  Jeffrey Weitz, President of ISTH presented a late-breaking abstract about the medicine Abelacimab.

The QUAZAR AML-001 Maintenance Trial

Prof. Eytan Stein talked about maintenance therapy for acute myeloid leukemia.

Idecabtagene vicleucel, a BCMA-​directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma

Prof. Oriol speaks about the updated results of KarMMa trial.

Novelties in the treatment of Multiple Myeloma

Prof. Ocio give us a brief overview about the main messages of the studies presented on EHA 2021 regarding multiple myeloma.

Treatment of hematological malignancies in 2021

Prof. Corradini speaks about the advance of CAR T-cell therapies and T-cell engaging antibodies.

Novelties in the treatment of chronic myeloid leukemia

Prof. Saglio speaks about the latest news came out from the EHA meeting in the field of CML treatment.

Novelties in the treatment of follicular lymphoma

Prof. Hübel speaks about the latest news came out from the EHA meeting in the field of follicular lymphoma treatment.

Harnessing the immune system in multiple myeloma: CAR T-cell therapy and bispecific antibodies

Prof. Leleu  speaks about the clinical and practical aspects of the topic.

Results from the JAKARTA and JAKARTA2 trials

Overall and progression-free survival in patients treated with fedratinib as first-line myelofibrosis therapy and after prior ruxolitinib.

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study: A Perioperative Management Plan for Patients with Atrial Fibrillation Who Are Receiving a Direct Oral Anticoagulant

Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Best of ASH

Long Term Follow-up after SCRI-CAR19v1 Reveals Late Recurrences As Well As a Survival Advantage to Consolidation with HCT after CAR T Cell Induced Remission

A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes

Initial Report of the Beat AML Umbrella Study for Previously Untreated AML: Evidence of Feasibility and Early Success in Molecularly Driven Phase 1 and 2 Studies

Multicenter Microbiota Analysis Indicates That Pre-HCT Microbiota Injury Is Prevalent across Geography and Predicts Poor Overall Survival

Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)